

Journal Pre-proof

Cutaneous manifestations in COVID-19: Lessons learned from current evidence

Poonkiat Suchonwanit, MD, Kanchana Leerunyakul, MD, Chaninan Kositkuljorn, MD

PII: S0190-9622(20)30710-6

DOI: <https://doi.org/10.1016/j.jaad.2020.04.094>

Reference: YMJD 14525

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 20 April 2020

Accepted Date: 21 April 2020

Please cite this article as: Suchonwanit P, Leerunyakul K, Kositkuljorn C, Cutaneous manifestations in COVID-19: Lessons learned from current evidence, *Journal of the American Academy of Dermatology* (2020), doi: <https://doi.org/10.1016/j.jaad.2020.04.094>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 by the American Academy of Dermatology, Inc.



Article type: Letter - Notes and Comments

Title: Cutaneous manifestations in COVID-19: Lessons learned from current evidence

Authors: Poonkiat Suchonwanit, MD, Kanchana Leerunyakul, MD, Chaninan Kositkuljorn, MD

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand

Corresponding author: Poonkiat Suchonwanit, MD

Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University.

270 Rama VI Road, Ratchathewi, Bangkok, Thailand 10400.

Phone: 66-2-201-1141 Fax: 66-2-201-1211 ext 4

E-mail: poonkiat@hotmail.com

Funding sources: This article has no funding source.

Conflicts of Interest: The authors have no conflict of interest to declare.

Manuscript word count: 484

Number of tables: 2

Number of references: 5

Cutaneous manifestations in COVID-19: Lessons learned from current evidence

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is a significant global concern. As of April 19, 2020, a total of 2,241,359 accumulated cases and 152,551 deaths have been reported worldwide.¹ The clinical features of COVID-19 have been described in several articles. The disease typically presents with symptoms resembling other viral respiratory infections, most commonly with fever and dry cough. Severe patients may later develop acute respiratory distress syndrome that could progress to multiple organ failure with a relatively high mortality rate.² Additionally, the disease is associated with leukopenia, thrombocytopenia, and elevated D-dimer levels that increase the risk of venous thromboembolism.³ Emerging evidence suggests that the uncontrolled release of proinflammatory cytokines resulting in cytokine storm syndrome plays an immunopathogenic role in disease progression and the development of severe disease.⁴

Cutaneous manifestations are considered an infrequent presentation of COVID-19, being rarely described in the literature. They are probably underrecognized due to a lack of dermatology consultations in this group of patients. The first evidence of skin manifestations was reported in 2 patients with severe respiratory disease, in a study of 1,099 cases in China. However, neither characteristics, nor progression of the lesions were documented.² Since then, subsequent case reports and case series have described COVID-19-associated skin lesions in confirmed COVID-19 cases, including clinical features that indicate viral exanthems (ie, morbilliform rash, petechial rash co-existing with thrombocytopenia, erythematous-to-purpuric coalescing macules, widespread urticaria, and varicella-like vesicles) and vasculopathy-related skin manifestations (ie, peripheral cyanosis with bullae and dry gangrene, transient unilateral livedo reticularis, and red papules on fingers resembling chilblains). Other non-laboratory-confirmed COVID-19 cases showed urticaria and painful erythematous-to-violaceous patches evolving into tense vesicles or dark crusts. All cases reported so far are summarized in Table 1.

According to preexisting data, we can speculate that cutaneous manifestations in COVID-19 may present in 2 major groups regarding their pathomechanisms: (1) clinical features similar to viral exanthems, an immune response to viral nucleotides; and (2) cutaneous eruptions secondary to systemic consequences caused by COVID-19, especially vasculitis and thrombotic vasculopathy. Apart from the above-mentioned, patients with COVID-19 are more likely to increase the risk of adverse drug reactions and interactions of their treatment, causing secondary cutaneous reactions at any point during the course of the disease. Therefore, it is essential to identify clues that support either viral cause or drug eruption. Table 2 summarizes cutaneous reactions reported in proposed drugs for COVID-19 treatment.⁵

In summary, whether skin lesions in patients with COVID-19 are related with the virus remains unclear. Dermatologists should keep in mind that skin eruptions occurring in patients with COVID-19 could result from viral infections, systemic consequences, or prescribed drugs. Early recognition of cutaneous signs that are associated with severe complications and prompt management are essential to improve patient outcomes. Moreover, further clinical studies regarding skin manifestations in COVID-19 are required to comprehend the exact cutaneous features for more accurate diagnoses that may predict disease outcomes in particular patients.

Abbreviations

COVID-19: coronavirus disease 2019

Journal Pre-proof

References

1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 90. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200419-sitrep-90-covid-19.pdf?sfvrsn=551d47fd_2. Published April 19, 2020. Accessed April 20, 2020.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020. <https://doi.org/10.1056/NEJMoa2002032>.
3. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. *Circulation*. 2020. <https://doi.org/10.1161/CIRCULATIONAHA.120.046941>.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020. [https://doi.org/10.1016/s0140-6736\(20\)30628-0](https://doi.org/10.1016/s0140-6736(20)30628-0).
5. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020. <https://doi.org/10.1001/jama.2020.6019>.

Table legends

Table I. Summary of reported COVID-19 cases with cutaneous manifestations between January 1, 2020 and April 19, 2020

Table II. Summary of possible mucocutaneous adverse effects reported for proposed COVID-19 treatments

Table I. Summary of reported COVID-19 cases with cutaneous manifestations between January 1, 2020 and April 19, 2020

Authors	N	Age, y and sex	Cutaneous manifestations	Extracutaneous manifestations	Laboratory-confirmed COVID-19 case	Associated with disease severity	Skin biopsy	Progression	Article link
Reported cases with skin manifestations that indicate viral exantheams									
Guan et al	2 of 1,099	NA	NA	NA	Yes	Yes	No	NA	https://doi.org/10.1056/NEJMoa2002032
Joob and Wiwanitkit	1	NA	Skin rash with petechiae	Fever, thrombocytopenia, respiratory symptoms	Yes	NA	No	NA	https://doi.org/10.1016/j.jaad.2020.03.036
Recalciti	18 of 88	NA	Erythematous rash (n=14), widespread urticaria (n =3), chickenpox-like vesicles (n=1)	NA	Yes	No	No	NA	https://doi.org/10.1111/jdv.16387
Hunt and Koziatek	1	20, M	Diffuse non-pruritic erythematous morbilliform rash on trunk and extremities	Fever, multifocal pneumonia with decreased oxygen saturation	Yes	Yes	No	NA	https://doi.org/10.5811/cpcem.2020.3.47349
Mahé et al	1	64, F	erythematous rash on both antecubital fossa, trunk and axillary folds resembling symmetrical drug-related intertriginous and flexural exanthem	Fever, cough, asthenia, bilateral pneumonia	Yes	No	No	Improved within 5 days	https://doi.org/10.1111/jdv.16471
Jimenez-Cauhe et al	1	84, F	Mild pruriginous erythematous-purpuric, coalescing macules on the peri-axillary area	Bilateral pneumonia	Yes	NA	No	NA	https://doi.org/10.1016/j.jaad.2020.04.016
Marzano et	22	8-90;	Diffuse/scattered	Fever, cough, headache,	Yes	No	Yes	4-15 days	https://doi.o

al		16M and 6F	papulovesicular lesions on trunk (n=22) and extremities (n=4), mild itch (n=9), pain (n=2), burning (n=3)	weakness, coryza, dyspnea, hyposmia, hypogeusia, pharyngodynia, diarrhea, myalgia			(n=7)		rg/10.1016/j.jaad.2020.04.044
Lu et al	1	NA	Urticaria	Bilateral pneumonia with minimal symptom	No	No	No	NA	https://doi.org/10.1002/jmv.25776
Henry et al	1	27, F	Generalized urticaria on face and extremities	Odynophagia, arthralgia, chills, fever, chest pain	Yes	No	No	NA	https://doi.org/10.1111/jdv.16472
Fernandez-Nieto et al	1	32, F	Urticaria	NA	Yes	No	Yes	Improved within 5 days	https://doi.org/10.1111/jdv.16470
Hoehl et al	1 of 2	NA	Faint rash	Minimal pharyngitis	Yes	No	No	NA	https://doi.org/10.1056/NEJMc2001899
Reported cases with vasculopathy-related skin manifestations									
Zhang et al	7	49-71; 4M and 3F	Finger/toe cyanosis, skin bullae and dry gangrene	Fever, cough, dyspnea, diarrhea	Yes	Yes	No	NA	https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006
Mazzotta and Troccoli	1	13, M	Erythematous-violaceous rounded lesions on toes with 1 cm diameter tense blister, blackish crusts at 7 days later	Low-grade fever, muscle pain, headache	No	No	No	Regressed in 2 weeks	http://sectcv.es/wp-content/uploads/2020/04/acroischemia-ENG.pdf
Manalo et al	2	67, M	Transient non-pruritic blanching unilateral livedoid patch on right	Low-grade fever, nasal congestion, post-nasal drip, cough, hematuria	Yes	Yes	No	Resolved within 19 hours	https://doi.org/10.1016/j.jaad.2020.04

			thigh						.018
		47, F	Unilateral transient asymptomatic rash on right leg resembling livedo reticularis	Low-grade fever, mild headache, sinus pressure, anosmia	Yes	No	No	Resolved within 20 minutes	
Ma et al	1 of 2	69, M	Dry gangrene on right index finger	Fever, bilateral pneumonia, antiphospholipid syndrome with cerebral infarcts	Yes	Yes	No	NA	https://doi.org/10.1016/j.clim.2020.108408
Zhang et al	1 of 3	69, M	Ischemia on both lower limbs and digits of the left hand	Fever, bilateral pneumonia, diarrhea, headache, multiple cerebral infarcts, positive antiphospholipid antibodies	Yes	Yes	No	NA	https://doi.org/10.1056/NEJMc2007575
Alramthan and Aldaraji	2	27 and 35; 2F	Red-to-purple papules on the dorsal aspects of fingers (n=2), diffused erythema in the subungual area of the right thumb (n=1), clinical features resembling chilblains	None	Yes	No	No	NA	https://doi.org/10.1111/ced.14243
Estebanez et al	1	28, F	Confluent erythematous-yellowish papules on both heels, later developed into pruritic erythematous plaques resembling urticarial vasculitis	Dry cough, nasal congestion, fatigue, myalgia, arthralgia, diarrhea, ageusia, anosmia	Yes	No	No	NA	https://doi.org/10.1111/jdv.16474

M, male; F, female; NA, not available

Note: References supported this table are available from the corresponding author upon request.

Table II. Summary of possible mucocutaneous adverse effects reported for proposed COVID-19 treatments

Treatment	Mucocutaneous side effects
Chloroquine/hydroxychloroquine*	<ul style="list-style-type: none"> • Common: itching, hair loss • Less common: morbilliform rash, erythroderma, exfoliative dermatitis, urticaria, eczematous eruption, erythema annulare centrifugum, photosensitivity • Rare: acute generalized exanthematous pustulosis
Azithromycin*	<ul style="list-style-type: none"> • Rare: morbilliform rash
Lopinavir/ritonavir	<ul style="list-style-type: none"> • Common: morbilliform rash • Rare: acute generalized exanthematous pustulosis, hair loss
Corticosteroids	<ul style="list-style-type: none"> • Common: skin atrophy, acnetiform eruption, telangiectasia, petechiae, ecchymosis, striae, hirsutism
Tocilizumab	<ul style="list-style-type: none"> • Less common: anaphylaxis • Rare: morbilliform rash, erythroderma, leucocytoclastic vasculitis
Convalescent plasma	<ul style="list-style-type: none"> • Less common: morbilliform rash, itching, evanescent red spot

*Combination treatment increases the risk of QT prolongation.

Note: References supported this table are available from the corresponding author upon request.